---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-259302"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:07:16.638045+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC

## Summary
- Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.
- Potential regulatory and commercial milestones up to $335.5M, plus tiered double-digit royalties on net sales in APAC.
- Otsuka gains exclusive rights to develop and commercialize 4D-150 for wet AMD and DME in Japan, China, Australia, and other APAC markets.
- Phase 3 study 4FRONT-1 enrollment exceeds expectations: over 200 patients randomized as of Oct 30, 2025.
- FDMT retains full rights outside APAC, including US, Latin America, and Europe.

## SEC filing metadata
- accession: 0001193125-25-259302
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/0001193125-25-259302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/d41653d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-259302
- JSON: https://secwatch.observer/filing/0001193125-25-259302.json
- Plain text: https://secwatch.observer/filing/0001193125-25-259302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.